Dhawan Lab. at the Mowat Labs, Institute of Liver Studies, King's College Hospital, London, United Kingdom.
Expert Rev Gastroenterol Hepatol. 2020 Mar;14(3):185-196. doi: 10.1080/17474124.2020.1733975. Epub 2020 Mar 2.
: Hepatocyte transplantation (HT) is a promising alternative to liver transplantation for the treatment of liver-based metabolic diseases and acute liver failure (ALF). However, shortage of good-quality liver tissues, early cell loss post-infusion, reduced cell engraftment and function restricts clinical application.: A comprehensive literature search was performed to cover pre-clinical and clinical HT studies. The review discusses the latest developments to address HT limitations: cell sources from marginal/suboptimal donors to neonatal livers, differentiating pluripotent stem cells into hepatocyte-like cells, expansion, prevention of immune response to transplanted cells by encapsulation or using innate immunity-inhibiting agents, and enhancing engraftment through partial hepatectomy or irradiation.: To date, published data are highly encouraging specially the alginate-encapsulated hepatocyte treatment of children with ALF. Hepatocyte functions can be further improved through co-culturing with mesenchymal stromal cells. Moreover, genetic correction will enable the use of autologous cells in future personalized medicine.
: 肝细胞移植 (HT) 是治疗基于肝脏的代谢性疾病和急性肝衰竭 (ALF) 的一种很有前途的肝移植替代方法。然而，优质肝组织的短缺、输注后早期细胞丢失、细胞植入和功能减少限制了其临床应用。: 进行了全面的文献检索，涵盖了 HT 的临床前和临床研究。本综述讨论了最新的发展，以解决 HT 的局限性：从边缘/次优供体到新生儿肝脏的细胞来源、多能干细胞向肝细胞样细胞的分化、扩增、通过包裹或使用先天免疫抑制剂来防止对移植细胞的免疫反应，以及通过部分肝切除术或辐照来增强植入。: 迄今为止，发表的数据非常令人鼓舞，特别是藻酸盐包封的肝细胞治疗 ALF 儿童的效果。通过与间充质基质细胞共培养，可以进一步改善肝细胞的功能。此外，基因矫正将使未来的个性化医疗能够使用自体细胞。
